Share Twitter LinkedIn Facebook Email Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read